Lindsay, Lisa http://orcid.org/0000-0002-4999-1402
DuPont, Herbert L.
Moe, Christine L.
Alberer, Martin
Hatz, Christoph
Kirby, Amy E.
Wu, Henry M.
Verstraeten, Thomas
Steffen, Robert
Funding for this research was provided by:
Takeda Vaccines Inc.
Article History
Received: 15 November 2017
Accepted: 31 October 2018
First Online: 3 December 2018
Ethics approval and consent to participate
: Emory University Institutional Review Board, Protocol #00078678.University of Texas Health Science Center Committee for the Protection of Human Subjects, Houston, Texas. Ethische Kommission für die Nordwestschweiz, EKNZ, Basel, Switzerland. Kantonale Ethikkommission, Zuerich, Switzerland. Ethikkommission bei der LMU München, Munich, Germany. Written informed consent was obtained from all study particpants prior to enrollment.
: Not applicable.
: LL and TV are consultants for Takeda Vaccines Inc. CLM and AEK have received consulting fees from Takeda Vaccines Inc.HMW is the principal investigator at the Emory TravelWell Center site for an expanded access protocol for yellow fever vaccination funded by Sanofi Pasteur.HLD has received consulting fees from Salix/Valeant and BioK International and has grants through his university from Takeda, Rebiotix and Seres.RS has received consulting fees from Takeda Vaccines Inc. and also from other vaccine manufacturers not involved in norovirus projects. He has been coordinating investigator on behalf of Dr. Falk Pharma in a travelers’ diarrhea therapy study and served on advisory boards to Clasado and Host Therabiomics.MA has declared no competing interests.CH has declared no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.